On accelerated approval, in response to a question, Missling said that he likes the idea and that it will depend on the quality of signal and strength of the data coming out of the current trials. He also made a comparison to an oncology approval that involved a companion diagnostic that I thought was interesting, but didn’t quite entirely catch.
News 
Market Data 
Discover 
AI
